Options
The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma
ISSN
0923-7534
Date Issued
2022
Author(s)
Horwitz, S.
O'Connor, O.A.
Pro, B.
Advani, R.
Bartlett, N.L.
Christensen, J.H.
Morschhauser, F.
Domingo-Domenech, E.
Illidge, T.
DOI
10.1016/j.annonc.2021.12.002
